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 ABSTRACT 
 During normal cell metabolism, reactive oxygen species (ROS) are produced as a 
byproduct of oxidative phosphorylation. ROS are utilized in the cell as a signaling molecule and 
can be maintained at healthy levels by cellular antioxidants. However, when the cell experiences 
oxidative stress due to environmental or genetic conditions, levels of ROS can exceed healthy 
levels and inhibit necessary life functions by damaging biomolecules and cellular structures. This 
loss of function can lead to physiological decline and neurodegeneration, such as in diseases like 
Alzheimer’s, amyotrophic lateral sclerosis (ALS), and, potentially, Huntington’s disease. The 
following experiments use the model genetic organism Drosophila melanogaster to test whether 
ROS accumulation affects the symptoms of individuals infected with Huntington’s disease, 
compared with individuals fed a molecular antioxidant supplement, MitoQ. We found that while 
MitoQ was expected to alleviate symptoms of Huntington’s disease, individuals supplemented 
with MitoQ experienced delayed development and detrimental motor function across time 
independent of genotype or sex.  
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INTRODUCTION 
 Huntington’s disease (HD) is a genetic, autosomal dominant disorder caused by a mutant 
elongated polyglutamine repeat that causes cognitive and motor deterioration characterized by 
chorea (abrupt, unpredictable muscle movements), memory and comprehension complications, 
and, in later stages, complete deficiency of muscle movement (Novak and Tabrizi 2011). The 
wild-type allele contains less than 35 repeats, while individuals experiencing symptoms of HD 
will have 36+ repeats. Generally, longer repeats yield a larger phenotypic effect, although the 
number of repeats only explains 50-70% of the variability in phenotypic effect, the rest of which 
is due to environmental factors (Jimenez-Sanchez et al. 2017). This makes it difficult to estimate 
the age of onset, strength of symptoms, and survivability of each patient. While the average age 
of onset of symptoms occurs at 40 years, juvenile onset (20 years) and older onset (70 years) 
have been observed (Novak and Tabrizi 2011).  
Mutant HD alleles have a gain of function effect whereby the HD protein aggregates, 
leading to cell toxicity and neurodegeneration. Other similar neurodegenerative disorders such as 
Parkinson’s, Alzheimer’s and Amyotrophic Lateral Sclerosis (ALS) have been found to have 
similar toxicity due to protein aggregation, although the causal disease genes code for completely 
different proteins (Labbadia and Morimoto 2013). The aggregates are thought to cause cell death 
by activating the cell cycle (Jimenez-Sanchez et al 2017). It is hypothesized that the gain of 
function mutant allele in HD alters mitochondrial metabolism and can produce high levels of 
reactive oxygen species (ROS). Oxidative stress caused by elevated ROS can cause injury to the 
cell via DNA damage and inactivation of important enzymes due to the reactive character of 
ROS. On the other hand, ROS can also act as an essential signaling molecule for maintaining 
physiological functions in response to environmental changes. In the following research, we 
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investigated how the mitochondria balance levels of ROS between dangerously high and critical 
functional levels in a fruit fly genetic model of HD.  
In humans, HD presents life-altering, chronic symptoms categorized by motor and 
neurodegeneration. According to Ross and Tabrizi (2010), vital aspects of the CNS experience 
prolonged deterioration and atrophy in specific regions of the brain, specifically in juvenile-onset 
cases. Additionally, symptoms may include weight and muscle loss, metabolic impairments, and 
weakening of endocrine function (Ross and Tabrizi 2010). While no cure exists for HD, 
treatment involves symptomatic approaches. Physical and occupational therapies designed to 
maximize neural and motor function can improve symptoms, but deterioration is inevitable. 
Various drug therapies have also been studied to address specific symptoms that make daily life 
difficult. For instance, muscle relaxers can be utilized to aid the presence of chorea but will later 
exacerbate the onset of muscle weakening and decline (Novak and Tabrizi 2011).  
Despite detrimental factors present in the elongated form of HD, the wild-type gene has 
beneficial functions in neural development. The Huntington gene is crucial in embryo 
development and control of stem cell production. When elongation of the gene occurs by 
expansion of the polyglutamine repeat region, it not only induces activation of the mutant protein 
to form protein aggregates, but also causes a loss of function in the wild-type advantageous gene. 
The HD mutant allele thus has two effects - to increase cell toxic events and eliminating useful 
function.  
 Huntington’s Disease occurs in approximately 4-10 individuals per every 100,0000 and 
leaves many more children of non-symptomatic carriers at risk of inheriting the disease, as 
elongations can expand from generation to generation (Ross and Tabrizi 2010). The average 
survivability is around 15-20 years after the initial point when an individual begins showing 
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symptoms. In juvenile onset cases, the progression of the disease tends to be longer and death 
occurs within 10-15 years and additional symptoms such as seizures and learning disabilities 
apparent in the classroom can occur (NIH 2019). Although the onset of symptoms does not occur 
until generally after reproduction years (around age 40), the autosomal dominant nature of the 
disease allows the predictability of inheritance to be high with the use of genetic testing (Novak 
and Tabrizi 2011).  
  As mentioned, methods for treatment thus far have been exclusively symptomatic 
although many studies attempt to address the underlying source of symptoms, although many are 
unsuccessful in human patients. Cholinesterase inhibitors, which have been effectively utilized to 
treat cognition decline in Alzheimer’s patients, have been unsuccessful for similar patients of 
HD. An antibiotic, minocycline, functions as a caspase inhibitor and can hinder cell death. The 
antibiotic was predicted to be beneficial in preventing many symptoms of HD, but was also 
unsuccessful in studies on the model mouse system. Thus far, some of the more successful 
methods have been gene silencing of the elongated HD allele in model organisms such as 
Drosophila melanogaster (Jimenez-Sanchez et al. 2017).  
 More specific studies have explored the role of ROS and evading protein aggregation for 
treatment of symptoms. Reducing the expression of the detrimental Huntington gene and 
inhibiting protein aggregation is thought to alleviate progression of the disease (Novak and 
Tabrizi 2011). In a study done by Ehrnhoefer et al., green tea polyphenol (-)-epigallocatechin-3-
gallate (EGCG) was used to prevent the misfolding of proteins and proved successful in 
alleviating toxicity (Ehrnhoefer et al. 2006).  
Currently, it remains unknown whether one specific ROS or multiple are responsible for 
the damage in mitochondria that accompanies HD. The question remains whether antioxidants 
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work to target one (potentially incorrect) oxidant or several oxidants and only partially alleviate 
the problem caused by another more damaging molecule (Kumar and Ratan 2016). A molecular 
antioxidant supplement, MitoQ, has been studied to prolong life and prevent cell apoptosis in 
aging organisms. The molecule works to prevent the release of ROS from the mitochondria and 
decrease cell apoptosis that is a result of oxidative stress (Kelso et al. 2001). Here we 
investigated whether supplementing with MitoQ could mediate the neurodegenerative effects of 
mutant HD alleles expressed in the fruit fly model of HD. 
The Drosophila model for Huntington disease 
 Notable studies in the model organism Drosophila melanogaster have shown promising 
results when targeting ROS as a source of toxicity. An enzyme called superoxide dismutase 
functions to eliminate harmful ROS molecules during oxidative stress in the cells. Flies whose 
genes contained three copies coding for the overexpression of the superoxide dismutase enzyme 
(SOD) were observed to have a longer lifespan, less damage to proteins due to oxidative stress 
(leading to lower levels of aggregated, destructive proteins), and maintained physical capabilities 
into later stages of life (Orr and Sohal 1994). This study proves to be promising for future 
research that works to eliminate ROS to avoid the effects of aging. A similar project studied flies 
with ALS (a neurodegenerative disorder similar to HD) and successfully utilized the SOD 
overexpression to observe a longer lifespan and also noted that the organisms developed 
“resistance to oxidative stress,” suggesting that the flies had adapted to quench excessive ROS 
and correct for the effects of oxidation (Parkes et al 1998).  
  Although extensive research has provided essential insight into the function of 
Huntington’s Disease, there are still many gaps in information that could potentially provide the 
necessary material for understanding HD and similar disorders, as well as the role of oxidative 
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stress in general aging that we will attempt to determine in the following research. For instance, 
it is still unclear whether ROS is a cause or effect of HD disease progression. We are unsure 
whether ROS accumulates as a consequence of HD protein aggregates or whether oxidative 
stress as a result of the disease progression leads to high levels of ROS that in turn cause protein 
misfolding and cell death. Additionally, it is unknown whether eliminating ROS completely will 
have deleterious results in the cell due to the eradication of ROS that normally functions 
beneficial as a signaling molecule. Here we report the results of an experiment to test the 
hypothesis that mitochondrial quenching of free radicals may ameliorate some of the 
neurodegenerative consequences on Huntington disease progression in the Drosophila fly model. 
Hypothesis and specific aims 
 We used a well-studied genetic model for human HD in the fruit fly Drosophila 
melanogaster to analyze the features of ROS in diseased mitochondria and test the hypothesis 
that antioxidants can be used to combat the effects of oxidative damage in symptoms of HD. Our 
aims are to assess development time in HD-affected flies and non-HD individuals, with or 
without dietary MitoQ supplement. I predicted that development time would be slower in HD-
affected individuals, and this development delay would be ameliorated by the MitoQ antioxidant 
treatment. Our second aim was to quantify the survivorship of control and diseased flies in the 
presence or absence of MitoQ. My prediction was that non-diseased control flies would have the 
highest rate of survival, and that HD diseased flies given MitoQ treatment would experience 
greater survival than those lacking the drug treatment. My third aim was to assess the motor 
function of aging flies with and without the HD disease allele. My prediction was that the HD 
flies would demonstrate lower climbing heights than non-diseased individuals, due to their 
characteristically weakened coordination and movement. The MitoQ treatment was predicted to 
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ameliorate this deterioration, and I predicted that flies fed the dietary antioxidant would maintain 
better motor skills than those lacking dietary antioxidant.  
 
METHODS 
Drosophila rearing 
 Two genotypes were utilized in this experiment. The control genotype expressed a short 
polyglutamate allele (Htt-25) under a ubiquitous promoter and was predicted to exhibit no 
symptoms of Huntington disease (HD), while the HD genotype expressed a long polyglutamate 
allele (Htt-120) under a ubiquitous promoter and was predicted to exhibit symptoms of 
neurodegeneration (Marsh and Thompson 2004). Each genotype was exposed to two treatments. 
The first was a standard cornmeal-molasses-yeast Drosophila media on which the parent 
generation mated, and offspring developed into adulthood on the same control media. The 
second treatment reared offspring from egg to adult on Drosophila media containing 0.05 mM 
Mito-Q. This concentration was developed from previous experiments that found larger 
concentrations of Mito-Q to have toxic effects (Dalke & Montooth, unpublished results). The 
Mito-Q food is designed to function as an antioxidant and prevent lipid peroxidation by ROS in 
genetically compromised systems, but may also benefit healthy organisms to quench free 
radicals (Magwere et al 2006). All fly cultures were maintained at 22ºC. Five replicate vials were 
made for each genotype-treatment combination. 
Development time 
 To test the effect of Mito-Q on development time, each vial of flies (five per genotype-
treatment combination) was scored for both time to adult eclosion and percent survival. Methods 
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from similar research on development time were modified from Buchanan et al. (2018). Thirty 
female virgins of the Gal4-promoter genotype were collected and allowed to mate for 
approximately 2-3 days with males from each genotype containing the UAS-HD repeat (either 
Htt-25 or Htt-120). A total of five biological replicates containing 25 eggs of each genotype were 
collected as third-instar larvae and placed on each type of treatment medium. Larvae were 
assessed twice daily for the following days to measure number of larvae that developed into 
pupae and eventually the number of males and females that reached eclosion. Each data set (time 
in hours to pupation and time in hours to eclosion) was analyzed as well as the number of final 
individuals that reached eclosion as a percentage of the original 25. We used analysis of variance 
followed by Tukey's contrasts to assess the effects of genotype (Htt-20 control versus Htt-125 
disease), treatment (control versus 0.05 mM Mito-Q) and their interaction on development. 
Climbing assay and survival 
 Flies of each treatment were collected into 5 replicate groups of 10 individual males and 
10 individual females. Every two days for 14 days, the flies were counted and recorded for 
number of surviving individuals. Protocol from Feany and Bender (2000) were modified to 
measure fly climbing ability. Five biological replicate vials containing the living individuals at 
each of the time points were gently tapped down and flies were assessed by the height climbed 
15 seconds later using video recording. The height at which 50% of the flies had climbed in 
centimeters was recorded. Two technical replicates were taken of each of the 5 biological 
replicates, and the flies were given 2 minutes of recovery time between technical replicates. 
Technical replicates were averaged, and analysis of variance was used to test for the effects of 
genotype (Htt-20 control versus Htt-125 disease), treatment (control versus 0.05 mM Mito-Q) 
and their interaction on climbing ability.  
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RESULTS 
MitoQ delayed development time across genotypes 
 There was a significant difference in the amount of development time from third instar to 
pupation between non-treated individuals and Mito-Q treated individuals (Table 1a) in both the 
Htt-120 genotype and Htt-25 genotype. Flies receiving dietary supplement took longer to pupate 
than those receiving no dietary supplement. Genotype showed no significant effect in time to 
pupation. Additionally, there was some indication that the HD genotype also delayed larval 
development relative to the control genotype, but only in the flies treated with MitoQ (P= 0.016). 
This resulted in a significant genotype-treatment interaction (Table 1a), with MitoQ and the HD 
genotype combining to delay development in larvae to pupation.  
 Development time to adulthood was also significantly delayed in flies that received 
MitoQ treatment across genotypes. Females (Table 1b) and males (Table 1c) took longer to 
eclose when fed MitoQ (Table 1b). Males with the Htt-120 disease allele under control treatment 
developed to adulthood at a faster rate (P = 7.45*10-5), compared to males fed MitoQ, which 
showed no effect between genotypes (P = 0.977).  
 
 
Table 1A 
Hours to pupation 
                    Df Sum Sq Mean Sq F value    Pr(>F)     
genotype             1    181   181.2  1.3140  0.252271     
treatment            1   5200  5199.7 37.7032 1.791e-09 *** 
genotype:treatment   1   1066  1066.3  7.7315  0.005651 **  
Residuals          457  63026   137.9                       
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Table 1B 
Hours to eclosion (female) 
                    Df Sum Sq Mean Sq F value    Pr(>F)     
genotype             1    197   196.9  0.6482    0.4216     
treatment            1  14313 14313.1 47.1206 6.417e-11 *** 
genotype:treatment   1     33    32.9  0.1082    0.7425     
Residuals          225  68345   303.8        
 
Table 1C 
Hours to eclosion (male) 
                    Df  Sum Sq Mean Sq  F value    Pr(>F)     
genotype             1  2337.0  2337.0  17.3277 4.582e-05 *** 
treatment            1 22360.1 22360.1 165.7894 < 2.2e-16 *** 
genotype:treatment   1  1135.4  1135.4   8.4182  0.004109 **  
Residuals          211 28457.7   134.9           
 
MitoQ treatment was unfavorable in development time across genotypes and sexes. Time to pupation (A) was 
delayed in individuals under antioxidant supplements and no difference was seen between genotypes. Time to 
adulthood in females (B) and males (C) showed significant negative effect due to MitoQ supplement. However, in 
males the effect of the HD allele was ameliorated by MitoQ treatment.  
 
MitoQ had a detrimental effect on climbing activity 
 Although it was predicted that MitoQ would work to quench free radicals and ameliorate 
the negative symptoms caused by oxidative stress in HD affected individuals, we observed that 
the dietary supplement had an overall negative effect on climbing ability across all sexes and 
genotypes. Initially, climbing ability was significantly negatively affected by MitoQ treatment 
(Pfemales = 0.00048; Pmales = 0.018). At day 14 of the study, MitoQ treatment continued to 
negatively affect climbing height compared to control treatment individuals (Pfemales = 0.00026; 
Pmales = 0.029). The only effect of the Htt-120 disease allele was in females on day 14 under 
MitoQ treatment (P = 0.0073), while those fed a control diet showed no difference in climbing 
between genotypes. This effect was strongest in females, but also could be seen as a trend in 
males (Figure 1).  
10 
 
Fig. 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Female (A) and male (B) climbing ability was statistically different between individuals on MitoQ treatment diet vs. 
control diet. Day 14 shows deterioration of motor function in HD individuals, specifically under MitoQ treatment. 
The effect of MitoQ was greater in males than females. 
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DISCUSSION 
 Development time was observed to be significantly longer in individuals treated with 
MitoQ antioxidant. The Drosophila model has been found to show longer development times in 
organisms that have compromised systems or have been subjected to environmental stress. Our 
findings show that MitoQ poses a detrimental effect on the organism, regardless of disease status 
or sex. In males, however, the MitoQ treatment did seem to ameliorate the development time 
effects of the Huntington disease allele. Although in control treatment flies the HD individuals 
surprisingly developed to adulthood faster than the non-HD individuals, MitoQ treatment 
removed any significant difference in genotypes, showing some potential in its capability as an 
effective antioxidant treatment.  
The detrimental effects on motor function observed in MitoQ-treated individuals, 
independent of genotype, is potentially a result of the over-compensation of its antioxidant role. 
By quenching free radicals unnecessarily, the cell is possibly losing essential and normal 
signaling mechanisms. This is especially apparent in non-diseased flies who had significantly 
decreased climbing ability when supplemented with MitoQ antioxidant. The cells may no longer 
be able to respond to the normal ROS signaling that protects cells under normal physiological 
conditions. Another possibility is that MitoQ is not functioning as an effective antioxidant, but is 
potentially disrupting mitochondrial function, as its mode of action is by accumulation in the 
mitochondrial lipid membrane bilayer. 
These results do not prove to be promising for individuals affected by Huntington’s 
Disease in the Drosophila model organism. Given these outcomes, we would not expect MitoQ 
to be used successful in drug therapies for HD individuals, although an alternative antioxidant or 
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genetic mechanism for upregulation of antioxidant enzymes may be a more promising therapy in 
alleviating the symptoms of neurodegenerative disorders. 
Our further research will continue to examine the molecular effect of MitoQ or other 
antioxidant dietary supplements on the antioxidant capacity and ROS levels within the 
mitochondria in this disease model. Assaying the organism’s antioxidant capacity is expected to  
reveal the degree to which HD-affected individuals are actually experiencing oxidative stress. 
Time points assessing longevity and motor function should be extended further to fully examine 
the role of Huntington’s disease in aging organisms and the deterioration of motor and cognitive 
function, as we observed the greatest effects only at our last time point in the experiment. Due to 
the apparent detrimental effects shown by the MitoQ antioxidant, studies should continue 
research for other antioxidants or various concentrations of MitoQ that will not cause detrimental 
effects on naturally occurring and essential metabolic mechanisms.  
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